Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and CAPOX in FGFR2/PD-L1-positive Metastatic Gastric Adenocarcinoma
NCT05859477Phase 2Recruiting
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in gastric adenocarcinoma. Started Jun 2022; status: recruiting.
02
Drugs
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT05859477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05859477.